🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Acute Myeloid Leukemia (AML)
Clinical trial register · China

Acute Myeloid Leukemia (AML) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 7 Beijing 7 Suzhou 7 Guangzhou 5 Tianjin 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Soochow University5 Peking University People's Hospital3 Institute of Hematology & Blood Diseases Hospital, China3 Ruijin Hospital2 AbbVie2
Site location
Shanghai7 Beijing7 Suzhou7 Guangzhou5 Tianjin5
All 26 locations
Target enrolment
to

Acute Myeloid Leukemia (AML) trials in China

36 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
NCT07813390Acute Myeloid Leukemia (AML)
DrugsHomoharringtonine·Lisaftoclax·Azacitidine
Guangdong Second Provincial General Hospital
Phase 2
73
Guangzhou
2026-09-01
By invitation
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
NCT07784309Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
13
Tianjin
2026-08-15
Recruiting
Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT07668557Acute Myeloid Leukemia (AML)
iCell Gene Therapeutics
Phase 1
18
Nanchang
2026-06-10
Recruiting
Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis
NCT07670130Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2026-06-01
Recruiting
VABu Conditioning in Elderly AML HSCT
NCT07583888Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 2/3
20
Suzhou
2026-05-07
Recruiting
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
NCT07463651Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance Therapy
DrugsSorafenib·Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3
594
Suzhou, Shanghai
2026-05-01
Not yet open
VAH vs VA in Newly Diagnosed Elderly AML
NCT07469046Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3
308
Shanghai
2026-04-10
Not yet open
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
NCT07507825Acute Myeloid Leukemia (AML)
First People's Hospital of Hangzhou
Phase 2
61
Hangzhou
2026-03-31
Recruiting
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
NCT07500441Acute Myeloid Leukemia (AML)
Peking University People's Hospital
Observational
100
Beijing
2026-03-20
Not yet open
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
NCT07486726Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)
DrugsAclarubicin·Azacitidine·Venetoclax
Shanghai Jiao Tong University School of Medicine
Phase 1/2
112
Shanghai
2026-03-15
Not yet open
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479Acute Myeloid Leukemia (AML)
DrugsIdarubicin·Mitoxantrone Hydrochloride Liposome·Cytarabine·Azacitidine
The First Affiliated Hospital of Soochow University
Phase 3
204
Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing
2026-03-10
By invitation
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
NCT07651163Acute Myeloid Leukemia (AML), Lisaftoclax
DrugsAclarubicin·Homoharringtonine·Daunorubicin·Lisaftoclax
First Affiliated Hospital of Zhejiang University
Phase 2/3
450
Hangzhou
2026-03-01
Not yet open
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
NCT07505160Acute Myeloid Leukemia (AML)
DrugsHomoharringtonine·Decitabine
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
35
Hangzhou
2026-03
Active, closed
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia
NCT07458542Acute Myeloid Leukemia (AML)
DrugAzacitidine
Bristol-Myers Squibb
Observational
44
Hong Kong
2025-12-09
Recruiting
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
NCT06641648Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, NK Cell
Peking University First Hospital
Phase 1
12
Beijing
2025-11-01
Recruiting
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT07198867Acute Myeloid Leukemia (AML), CAR-T Cell Therapy
First Affiliated Hospital of Zhejiang University
Phase 1
20
Hangzhou
2025-09-30
Recruiting
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
NCT07451912Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML
DrugVenetoclax
The First Affiliated Hospital of Soochow University
Phase 1/2
29
Suzhou
2025-09-15
Recruiting
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
NCT07761533Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
Chaser Therapeutics, Inc.
Phase 1/2
29
Hangzhou
2025-09-08
Not yet open
Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
NCT07087847Acute Leukemia, Acute Leukemia Refractory, Acute Myeloid Leukemia (AML), ALL (Acute B-Lymphoblastic Leukemia)
Ruijin Hospital
Not applicable
18
Shanghai
2025-09-01
Recruiting
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07153068T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
12
Tianjin
2025-06-28
Recruiting
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07109518Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
NCT07537738Acute Myeloid Leukemia (AML), MLL Rearrangement
Peking University People's Hospital
Observational
210
Beijing
2025-06-01
Recruiting
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
NCT06990321Acute Myeloid Leukemia (AML), Elderly
DrugsIntermediate- Cytarabine·Venetoclax
Yehui Tan
Phase 3
68
Changchun
2025-06-01
Recruiting
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
NCT07023588Acute Myeloid Leukemia (AML)
DrugVenetoclax
Yehui Tan
Phase 2
70
Changchun
2025-06-01
Recruiting
Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
NCT06869265Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)
Peking University People's Hospital
Phase 2
56
Beijing
2025-05-01
Not yet open
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
NCT06702098Acute Myeloid Leukemia (AML)
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1
10
Guangzhou
2024-11-25
Not yet open
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT06652685Acute Myeloid Leukemia (AML)
Ruijin Hospital
Phase 2
218
Shanghai
2024-10-30
Recruiting
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
NCT06642025Acute Myeloid Leukemia (AML), CAR-T
Zhimin Zhai
Phase EARLY_PHASE1
9
Hefei
2024-09-01
Not yet open
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
NCT06387420ACUTE MYELOID LEUKEMIA; AML
DrugsAK117·Azacitidine·Venetoclax
Akeso
Phase 1/2
180
Tianjin
2024-04-29
Recruiting
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
NCT07205523Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML), Leukemias, Acute Myeloid, Myeloid Leukemias, Acute
Yigeng Cao,MD,PhD
Observational
1,000
Xining
2023-09-01
Recruiting
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
NCT06760260Acute Myeloid Leukemia (AML)
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1
7
Suzhou
2022-01-26
Active, closed
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
2020-11-19
Recruiting
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
NCT04275518Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.
Phase 1
102
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Nanchang, Changchun
2020-07-06
Recruiting
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
NCT06550713Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
DrugAzacitidine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
100
Beijing, Shijiazhuang, Harbin, Shanghai, Chengdu, Tianjin
2019-10-22
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/acute-myeloid-leukemia-aml

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies listing the condition Acute Myeloid Leukemia (AML).

How many Acute Myeloid Leukemia (AML) trials are recruiting in China?

20 of the 36 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 9 have not yet opened recruitment, 4 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Acute Myeloid Leukemia (AML)), 36 studies
PhaseStudiesRecruitingShare
Phase 18622.2%
Phase 26216.7%
Observational5413.9%
Phase 1/25313.9%
Phase 35213.9%
Phase EARLY_PHASE1328.3%
Phase 2/3215.6%
Not applicable102.8%
Phase 4102.8%

Most active sponsors

Lead sponsors with the most studies (Acute Myeloid Leukemia (AML))
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Soochow University54
Institute of Hematology & Blood Diseases Hospital, China32
Peking University People's Hospital33
AbbVie20
First Affiliated Hospital of Zhejiang University21
Ruijin Hospital20
Yehui Tan22
Akeso10
Ascentage Pharma Group Inc.11
Bristol-Myers Squibb10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.